Püsküllüoğlu Mirosława, Swiderska Katarzyna, Konieczna Aleksandra, Streb Joanna, Grela-Wojewoda Aleksandra, Rudzinska Agnieszka, Dobrzańska Jolanta, Pacholczak-Madej Renata, Mucha-Malecka Anna, Kunkiel Michał, Mitus Jerzy W, Jarząb Michał, Ziobro Marek
Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, 31-115 Krakow, Poland.
Breast Cancer Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.
Oncol Lett. 2024 Mar 8;27(5):198. doi: 10.3892/ol.2024.14331. eCollection 2024 May.
Metaplastic breast cancer (BC-Mp), which includes a range of epithelial and mixed epithelial-mesenchymal tumours, are rare malignancies with an unfavourable prognosis. The limited literature on BC-Mp focuses mainly on retrospective data for radically treated patients. Notably absent are studies dedicated to the palliative treatment of BC-Mp with distant metastases. The present retrospective study investigated treatment modalities and prognosis in a multi-centre cohort of 31 female participants diagnosed with distant metastatic BC-Mp, including 7 patients with metastatic disease. The median age of the patients was 61 years (range, 33-87 years), with 38.7% presenting local lymph node involvement. Lungs were the most common site for the metastatic disease (61.3%). Median Ki-67 index was 50% (range, 35-70%), and 80.7% of cases were classified as grade 3. Human epidermal growth factor receptor 2 (HER2) and estrogen receptor were detected in 12.9 and 6.5% of cases, respectively. A total of 62.4% of patients received first-line palliative systemic treatment. The 1- and 2-year overall survival (OS) were 38.5 and 19.2%, respectively. Receiving ≥1 line of palliative treatment was significantly associated with improved OS (P<0.001). Factors such as age, Ki-67 index, HER2 or hormonal status, presence of specific epithelial or mesenchymal components, location of metastases or chemotherapy regimen type did not influence OS. The present study provided insights into the clinicopathological profile, systemic treatment experience, prognostic factors and OS data of BC-Mp with distant metastases, emphasizing the imperative for clinical trials in this population.
化生性乳腺癌（BC-Mp）包括一系列上皮性和上皮-间充质混合性肿瘤，是预后不良的罕见恶性肿瘤。关于BC-Mp的文献有限，主要集中在接受根治性治疗患者的回顾性数据上。值得注意的是，缺乏专门针对伴有远处转移的BC-Mp姑息治疗的研究。本回顾性研究调查了31名被诊断为远处转移性BC-Mp的女性参与者的多中心队列中的治疗方式和预后，其中包括7名患有转移性疾病的患者。患者的中位年龄为61岁（范围33 - 87岁），38.7%的患者出现局部淋巴结受累。肺是转移性疾病最常见的部位（61.3%）。Ki-67指数中位数为50%（范围35 - 70%），80.7%的病例被分类为3级。分别在12.9%和6.5%的病例中检测到人表皮生长因子受体2（HER2）和雌激素受体。共有62.4%的患者接受了一线姑息性全身治疗。1年和2年总生存率（OS）分别为38.5%和19.2%。接受≥1线姑息治疗与OS改善显著相关（P<0.001）。年龄、Ki-67指数、HER2或激素状态、特定上皮或间充质成分的存在、转移部位或化疗方案类型等因素不影响OS。本研究提供了关于伴有远处转移的BC-Mp的临床病理特征、全身治疗经验、预后因素和OS数据的见解，强调了对该人群进行临床试验的必要性。
